Jenner & Block

 

Mr. Fogel's significant representative matters include:

  • Represented Ethicon, Inc. and Omrix Biopharmaceuticals in patent litigation involving hemostatic bandages.
  • Represented Coherus BioSciences in patent and trade secret litigation concerning Udeynca, a biosimilar to Amgen’s Neulasta biological drug product that is used to treat neutropenia.
  • Represented Coherus BioSciences in IPR proceedings related to patents covering AbbVie dosing regimens related to Humira dosing regimens.
  • Represented Genzyme in patent litigation concerning Fabrazyme, a drug produced by recombinant DNA technology that is used to treat Fabry disease.
  • Represented Wyeth Pharmaceuticals, Inc. in ANDA litigation involving Tygacil, a tetracycline class antibiotic.
  • Represented Wyeth Pharmaceuticals, Inc. in patent litigation concerning Refacto, a hemophilia drug produced by recombinant DNA technology.
  • Represented Kissei Pharmaceutical Co. in ANDA litigation involving Rapaflo, a drug used to treat benign prostatic hyperplasia (BPH).
  • Represented AstraZeneca in ANDA litigation involving Pulmicort Respules, a drug used to treat pediatric asthma.
  • Represented Alza Corp. and McNeil-PPC Inc. in ANDA litigation involving Concerta, a drug used to treat attention deficit disorder.
  • Represented Schering Corp. in ANDA litigation concerning Zetia, a drug used to treat high cholesterol
  • Represented Johnson & Johnson and Cordis Corporation in patent litigation concerning the design and use of angioplasty catheters.
  • Represented NEC Display Solutions of America, Inc. in patent litigation related to remote display advertising systems.
  • Represented a large international communications client in an ITC investigation, relating to multiple patents directed to features of wireless devices.